JP2015532642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532642A5 JP2015532642A5 JP2015527533A JP2015527533A JP2015532642A5 JP 2015532642 A5 JP2015532642 A5 JP 2015532642A5 JP 2015527533 A JP2015527533 A JP 2015527533A JP 2015527533 A JP2015527533 A JP 2015527533A JP 2015532642 A5 JP2015532642 A5 JP 2015532642A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- cycloalkyl
- optionally
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 85
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 102000004311 liver X receptors Human genes 0.000 claims 11
- 108090000865 liver X receptors Proteins 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 6
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 230000001028 anti-proliverative effect Effects 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 102000013918 Apolipoproteins E Human genes 0.000 claims 2
- 108010025628 Apolipoproteins E Proteins 0.000 claims 2
- 229940125431 BRAF inhibitor Drugs 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 2
- 239000012824 ERK inhibitor Substances 0.000 claims 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091025686 miR-199a stem-loop Proteins 0.000 claims 2
- 108091083769 miR-199a-1 stem-loop Proteins 0.000 claims 2
- 108091047470 miR-199a-2 stem-loop Proteins 0.000 claims 2
- 108091048350 miR-199a-3 stem-loop Proteins 0.000 claims 2
- 108091056793 miR-199a-4 stem-loop Proteins 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 2
- 229960003862 vemurafenib Drugs 0.000 claims 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100031168 CCN family member 2 Human genes 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229940127007 Compound 39 Drugs 0.000 claims 1
- 102100029715 DnaJ homolog subfamily A member 4 Human genes 0.000 claims 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 1
- 101000866014 Homo sapiens DnaJ homolog subfamily A member 4 Proteins 0.000 claims 1
- 101001039207 Homo sapiens Low-density lipoprotein receptor-related protein 8 Proteins 0.000 claims 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 claims 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 1
- 102100040705 Low-density lipoprotein receptor-related protein 8 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims 1
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 1
- 239000002257 antimetastatic agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 229940127573 compound 38 Drugs 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000004445 cyclohaloalkyl Chemical group 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- -1 ipilimumab Chemical compound 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 108091083606 miR-1908 stem-loop Proteins 0.000 claims 1
- 108091023818 miR-7 stem-loop Proteins 0.000 claims 1
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682339P | 2012-08-13 | 2012-08-13 | |
| US61/682,339 | 2012-08-13 | ||
| US201361784057P | 2013-03-14 | 2013-03-14 | |
| US61/784,057 | 2013-03-14 | ||
| PCT/US2013/054690 WO2014028461A2 (en) | 2012-08-13 | 2013-08-13 | Treatment and diagnosis of melanoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018023820A Division JP6523502B2 (ja) | 2012-08-13 | 2018-02-14 | メラノーマの処置および診断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532642A JP2015532642A (ja) | 2015-11-12 |
| JP2015532642A5 true JP2015532642A5 (https=) | 2016-09-29 |
| JP6320382B2 JP6320382B2 (ja) | 2018-05-09 |
Family
ID=50101591
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527533A Active JP6320382B2 (ja) | 2012-08-13 | 2013-08-13 | メラノーマの処置および診断 |
| JP2018023820A Active JP6523502B2 (ja) | 2012-08-13 | 2018-02-14 | メラノーマの処置および診断 |
| JP2019083874A Active JP7005551B2 (ja) | 2012-08-13 | 2019-04-25 | メラノーマの処置および診断 |
| JP2021105207A Active JP7472080B2 (ja) | 2012-08-13 | 2021-06-24 | メラノーマの処置および診断 |
| JP2023223727A Pending JP2024041827A (ja) | 2012-08-13 | 2023-12-28 | メラノーマの処置および診断 |
| JP2026001136A Pending JP2026062949A (ja) | 2012-08-13 | 2026-01-06 | メラノーマの処置および診断 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018023820A Active JP6523502B2 (ja) | 2012-08-13 | 2018-02-14 | メラノーマの処置および診断 |
| JP2019083874A Active JP7005551B2 (ja) | 2012-08-13 | 2019-04-25 | メラノーマの処置および診断 |
| JP2021105207A Active JP7472080B2 (ja) | 2012-08-13 | 2021-06-24 | メラノーマの処置および診断 |
| JP2023223727A Pending JP2024041827A (ja) | 2012-08-13 | 2023-12-28 | メラノーマの処置および診断 |
| JP2026001136A Pending JP2026062949A (ja) | 2012-08-13 | 2026-01-06 | メラノーマの処置および診断 |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US9526710B2 (https=) |
| EP (3) | EP3626309B1 (https=) |
| JP (6) | JP6320382B2 (https=) |
| CN (3) | CN116271053A (https=) |
| AU (4) | AU2013302861A1 (https=) |
| CA (2) | CA3211094A1 (https=) |
| DK (1) | DK2882496T3 (https=) |
| ES (2) | ES2765573T3 (https=) |
| HU (1) | HUE046292T2 (https=) |
| WO (1) | WO2014028461A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102089444A (zh) | 2008-05-14 | 2011-06-08 | 德玛泰克国际公司 | 利用核酸分析方法来诊断黑素瘤和太阳能雀斑 |
| SG10201607345YA (en) | 2012-03-02 | 2016-11-29 | Ralexar Therapeutics Inc | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
| AU2013302861A1 (en) * | 2012-08-13 | 2015-03-05 | The Rockefeller University | Treatment and diagnosis of melanoma |
| JP2016532713A (ja) | 2013-09-04 | 2016-10-20 | アレクサー セラピューティクス， インク． | 肝臓ｘ受容体（ｌｘｒ）調節因子 |
| RS60479B1 (sr) | 2013-09-04 | 2020-08-31 | Ellora Therapeutics Inc | Modulatori receptora x jetre (lxr) |
| WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
| US20190125745A1 (en) * | 2014-12-17 | 2019-05-02 | Rgenix, Inc. | Treatment and diagnosis of cancer |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| US10709428B2 (en) | 2015-05-01 | 2020-07-14 | Dermtech, Inc. | Non-invasive skin collection system |
| JP2018527016A (ja) * | 2015-06-24 | 2018-09-20 | オックスフォード バイオダイナミックス リミテッド | 染色体相互作用の検出 |
| EP3314025A4 (en) * | 2015-06-29 | 2019-04-24 | Regents of the University of Minnesota | APOBEC3B MUTAGENESIS AND IMMUNOTHERAPY |
| EP3313993A4 (en) | 2015-06-29 | 2019-06-19 | Regents of the University of Minnesota | ANTI-APOBEC3 ANTIBODIES AND METHOD OF PREPARATION AND USE |
| EP3402477A4 (en) * | 2016-01-11 | 2019-08-21 | The Rockefeller University | METHOD FOR THE TREATMENT OF DISEASES RELATED TO MYELOID-DERIVED SUPPRESSOR CELLS |
| US11208468B2 (en) | 2016-02-18 | 2021-12-28 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI910495B (zh) * | 2016-05-13 | 2026-01-01 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| US10960008B2 (en) * | 2016-07-11 | 2021-03-30 | Dana-Farber Cancer Institute, Inc. | Methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3KBETA and anti-immune checkpoint agents |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| EP3589280B1 (en) * | 2017-03-03 | 2024-02-07 | Inspirna, Inc. | Formulations with improved stability |
| CN106890315B (zh) * | 2017-03-16 | 2019-09-06 | 北京热休生物技术有限公司 | Apo-e蛋白及其多肽在治疗与预防癌症中的应用 |
| EP3624896A4 (en) | 2017-05-16 | 2021-03-31 | Biomed Valley Discoveries, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS |
| CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
| CA3090785A1 (en) | 2018-02-14 | 2019-08-22 | John Daniel Dobak Iii | Novel gene classifiers and uses thereof in non-melanoma skin cancers |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| JP7654202B2 (ja) * | 2019-02-28 | 2025-04-01 | ザ ロックフェラー ユニバーシティー | がんの予後及び治療におけるａｐｏｅ遺伝子型決定 |
| JP2022524641A (ja) | 2019-03-26 | 2022-05-09 | ダームテック，インク． | 皮膚癌における新規な遺伝子分類子とその使用 |
| EP3752524A4 (en) * | 2019-04-27 | 2021-11-24 | Ocugen, Inc. | ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASE |
| CN110218235B (zh) * | 2019-05-09 | 2020-09-25 | 中山大学 | 一种化合物及其制备方法和作为荧光偏振探针在LXRβ配体筛选中的应用 |
| CA3150729A1 (en) * | 2019-09-11 | 2021-03-18 | Inspirna, Inc. | Methods of treating cancer |
| US12582667B2 (en) | 2019-09-27 | 2026-03-24 | The Rockefeller University | Compositions and methods to treat metastatic gastrointestinal cancer |
| RU2716811C1 (ru) * | 2019-11-14 | 2020-03-16 | федеральное государственное бюджетное образовательное учреждение высшего образования "Новгородский государственный университет имени Ярослава Мудрого" | Способ ранней диагностики поверхностно распространяющихся меланом |
| TWI888447B (zh) | 2019-12-13 | 2025-07-01 | 美商因思博納公司 | 金屬鹽及其用途 |
| EP4081302A4 (en) * | 2019-12-23 | 2025-01-29 | University Of Massachusetts | OLIGONUCLEOTIDES FOR TISSUE-SPECIFIC GENE EXPRESSION MODULATION |
| CN116194779A (zh) * | 2020-08-21 | 2023-05-30 | 瑞士杰特贝林生物制品有限公司 | 用于检测血红素结合蛋白:血红素复合物的cd91多肽 |
| EP4376953A1 (en) * | 2021-07-30 | 2024-06-05 | Alnylam Pharmaceuticals, Inc. | Peptide ligands for cns and ocular delivery of rnai compounds |
| CN114276999A (zh) * | 2022-03-03 | 2022-04-05 | 中日友好医院(中日友好临床医学研究所) | 黑素瘤细胞株及其制备方法 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5324731A (en) | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| US5676978A (en) | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5215882A (en) | 1989-11-30 | 1993-06-01 | Ortho Diagnostic Systems, Inc. | Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| DE69621507T2 (de) | 1995-03-28 | 2003-01-09 | Japan Science And Technology Corp., Kawaguchi | Verfahren zur molekularen Indexierung von Genen unter Verwendung von Restriktionsenzymen |
| US5843974A (en) * | 1995-06-06 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se |
| US5958342A (en) | 1996-05-17 | 1999-09-28 | Incyte Pharmaceuticals, Inc. | Jet droplet device |
| US6060240A (en) | 1996-12-13 | 2000-05-09 | Arcaris, Inc. | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom |
| US6090556A (en) | 1997-04-07 | 2000-07-18 | Japan Science & Technology Corporation | Method for quantitatively determining the expression of a gene |
| US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| ATE338118T1 (de) | 1997-12-12 | 2006-09-15 | Univ Western Ontario | Neues peptid, apoep1.b, zusammensetzungen und verwendungen davon |
| US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
| US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
| US6087112A (en) | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| US8257750B2 (en) | 1999-04-30 | 2012-09-04 | Kibow Biotech, Inc. | Calcium carbonate compositions for preventing or treating hyperphosphatemia |
| US6716622B2 (en) | 2000-07-18 | 2004-04-06 | Uab Research Foundation | Tissue-specific self-inactivating gene therapy vector |
| US20030027335A1 (en) | 2000-09-07 | 2003-02-06 | Ruley H. Earl | Genome engineering by cell-permeable DNA site-specific recombinases |
| WO2002024632A2 (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| AU2002219718A1 (en) | 2000-12-13 | 2002-06-24 | Sca Hygiene Products Zeist B.V. | Process for oxidising primary alcohols |
| JP2003033179A (ja) | 2001-07-05 | 2003-02-04 | Asahi Kasei Corp | 可逆的遺伝子導入ベクター |
| EP1575495A4 (en) | 2002-03-27 | 2009-12-02 | Smithkline Beecham Corp | COMPOUNDS AND METHODS |
| AU2003220558A1 (en) | 2002-03-27 | 2004-06-03 | Smithkline Beecham Corporation | Amide compounds and methods of using the same |
| US7560586B2 (en) | 2002-03-27 | 2009-07-14 | Smithkline Beecham Corporation | Acid and ester compounds and methods of using the same |
| ATE470722T1 (de) | 2002-07-19 | 2010-06-15 | Althea Technologies Inc | Strategien zur genexpressionsanalyse |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20040216178A1 (en) | 2003-03-03 | 2004-10-28 | Jones Stephen N | Regulation of mdm2 function |
| WO2005007877A2 (en) | 2003-07-18 | 2005-01-27 | University Of Massachusetts | Regulatable promoters for synthesis of small hairpin rna |
| BRPI0415563A (pt) | 2003-10-20 | 2007-01-02 | Nsgene As | método para o tratamento do mal de parkinson, uso de um vetor viral, vetor de expressão viral, composição farmacêutica, célula hospedeira isolada, linhagem de células de empacotamento, mamìfero não humano quimérico, dispositivo de cultura celular implantável, cápsula biocompatìvel, método para tratamento de uma doença do sistema nervoso, célula de mamìfero, e, método para produzir neurturin ou um seu equivalente funcional |
| AU2004298486A1 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
| FR2865736B1 (fr) | 2004-02-02 | 2006-07-14 | Synt Em | Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese |
| WO2005112620A2 (en) | 2004-05-18 | 2005-12-01 | Massachusetts Institute Of Technology | A cre-lox based method for conditional rna interference |
| WO2006004030A1 (ja) * | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | 組織因子産生抑制剤 |
| CN1980665A (zh) | 2004-07-07 | 2007-06-13 | 默克公司 | 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法 |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| ATE415385T1 (de) | 2004-10-01 | 2008-12-15 | Hoffmann La Roche | Hexafluorisopropanolsubstituierte etherderivate |
| WO2006066779A1 (en) | 2004-12-22 | 2006-06-29 | F.Hoffmann-La Roche Ag | Novel cyclohexane derivatives |
| US20090029945A2 (en) | 2005-01-10 | 2009-01-29 | Astrazeneca Ab | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators |
| JP2008526841A (ja) | 2005-01-10 | 2008-07-24 | アストラゼネカ アクチボラグ | 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体 |
| SE0500056D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 4 |
| SE0500058D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| RU2007131400A (ru) | 2005-03-01 | 2009-04-10 | Вайет (Us) | Соединения циннолина и их применение в качестве модуляторов х-рецепторов печени |
| US8318760B2 (en) | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
| BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| CN101309915A (zh) | 2005-11-14 | 2008-11-19 | Irm责任有限公司 | 作为lxr调节剂的化合物和组合物 |
| WO2007081335A1 (en) | 2006-01-12 | 2007-07-19 | Merck & Co., Inc. | Therapeutic compounds for treating dyslipidemic conditions |
| ATE495197T1 (de) | 2006-03-20 | 2011-01-15 | Cepep Iii Ab | Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel |
| WO2008011071A2 (en) * | 2006-07-19 | 2008-01-24 | The Regents Of The University Of California | Interactions of hedgehog and liver x receptor signaling pathways |
| TW200825054A (en) | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
| KR20090086084A (ko) | 2006-11-30 | 2009-08-10 | 코와 가부시키가이샤 | 치환 카르비놀 화합물 |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| JP2008179562A (ja) | 2007-01-24 | 2008-08-07 | Kowa Co | Ｌｘｒアゴニスト |
| US8993628B2 (en) | 2007-02-23 | 2015-03-31 | City Of Hope | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof |
| EP2142517A2 (en) | 2007-05-18 | 2010-01-13 | Wyeth | Quinazoline compounds |
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| JP5220858B2 (ja) | 2007-08-13 | 2013-06-26 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ピペラジンアミド誘導体 |
| TW200922582A (en) | 2007-08-20 | 2009-06-01 | Organon Nv | N-benzyl, N'-arylcarbonylpiperazine derivatives |
| US8039493B2 (en) | 2007-09-27 | 2011-10-18 | Hoffmann-La Roche Inc. | Biaryl sulfonamide derivatives |
| EP2623599B1 (en) * | 2007-10-04 | 2019-01-02 | Roche Innovation Center Copenhagen A/S | Micromirs |
| CA2705152C (en) | 2007-11-09 | 2016-10-11 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| WO2009075836A2 (en) * | 2007-12-10 | 2009-06-18 | The Brigham And Women's Hospital, Inc. | Rap variants for drug delivery |
| JP2011507905A (ja) | 2007-12-21 | 2011-03-10 | ワイス・エルエルシー | ベンズイミダゾール化合物 |
| EP2231660A1 (en) | 2007-12-21 | 2010-09-29 | Wyeth LLC | Imidazo [1,2-a] pyridine compounds |
| WO2009086130A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth | Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors |
| US20100324073A1 (en) | 2007-12-21 | 2010-12-23 | Wyeth Llc | Pyrazolo [1,5-A] Pyrimidine Compounds |
| US7919509B2 (en) | 2008-02-29 | 2011-04-05 | Kowa Company, Ltd. | 2-oxochromene derivatives |
| US20090311187A1 (en) * | 2008-05-29 | 2009-12-17 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the Co-stimulatory pathway |
| WO2010002982A1 (en) * | 2008-07-01 | 2010-01-07 | Cognosci, Inc. | Methods of treating cancer with apoe peptides |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| WO2010101888A2 (en) * | 2009-03-02 | 2010-09-10 | Biocure Pharma, Llc | Methods and compositions for treatment of tumor metastasis |
| KR101676704B1 (ko) * | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| US9421218B2 (en) * | 2010-04-13 | 2016-08-23 | New York University | Compositions and methods for treatment of melanoma |
| US20130090258A1 (en) | 2010-06-16 | 2013-04-11 | National University Corporation Hamamatsu University School Of Medicines | Method for detecting colorectal tumor |
| EP2474617A1 (en) * | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| WO2013043569A1 (en) * | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| AU2013302861A1 (en) * | 2012-08-13 | 2015-03-05 | The Rockefeller University | Treatment and diagnosis of melanoma |
-
2013
- 2013-08-13 AU AU2013302861A patent/AU2013302861A1/en not_active Abandoned
- 2013-08-13 CA CA3211094A patent/CA3211094A1/en active Pending
- 2013-08-13 HU HUE13829165A patent/HUE046292T2/hu unknown
- 2013-08-13 ES ES13829165T patent/ES2765573T3/es active Active
- 2013-08-13 EP EP19189895.6A patent/EP3626309B1/en active Active
- 2013-08-13 CN CN202211715800.2A patent/CN116271053A/zh active Pending
- 2013-08-13 CN CN201380053478.4A patent/CN104780976B/zh active Active
- 2013-08-13 EP EP13829165.3A patent/EP2882496B1/en active Active
- 2013-08-13 CA CA2882292A patent/CA2882292C/en active Active
- 2013-08-13 WO PCT/US2013/054690 patent/WO2014028461A2/en not_active Ceased
- 2013-08-13 EP EP23155232.4A patent/EP4218935A1/en active Pending
- 2013-08-13 JP JP2015527533A patent/JP6320382B2/ja active Active
- 2013-08-13 DK DK13829165T patent/DK2882496T3/da active
- 2013-08-13 CN CN201811502066.5A patent/CN110037999B/zh active Active
- 2013-08-13 ES ES19189895T patent/ES2941477T3/es active Active
-
2014
- 2014-09-15 US US14/486,477 patent/US9526710B2/en active Active
- 2014-09-15 US US14/486,466 patent/US9399028B2/en active Active
-
2016
- 2016-08-04 US US15/228,643 patent/US9707195B2/en active Active
-
2017
- 2017-07-14 US US15/650,480 patent/US9962348B2/en active Active
-
2018
- 2018-01-26 US US15/881,231 patent/US10543183B2/en active Active
- 2018-02-14 JP JP2018023820A patent/JP6523502B2/ja active Active
- 2018-09-07 AU AU2018226488A patent/AU2018226488B2/en active Active
-
2019
- 2019-04-25 JP JP2019083874A patent/JP7005551B2/ja active Active
- 2019-12-23 US US16/725,493 patent/US10945978B2/en active Active
-
2020
- 2020-01-31 AU AU2020200715A patent/AU2020200715B2/en active Active
-
2021
- 2021-03-15 US US17/201,493 patent/US11865094B2/en active Active
- 2021-06-24 JP JP2021105207A patent/JP7472080B2/ja active Active
-
2022
- 2022-08-12 AU AU2022215282A patent/AU2022215282A1/en not_active Abandoned
-
2023
- 2023-12-28 JP JP2023223727A patent/JP2024041827A/ja active Pending
-
2024
- 2024-01-03 US US18/403,027 patent/US12502368B2/en active Active
-
2026
- 2026-01-06 JP JP2026001136A patent/JP2026062949A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015532642A5 (https=) | ||
| AU2009268469B2 (en) | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway | |
| Kurmis et al. | A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer | |
| McCubrey et al. | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance | |
| Michmerhuizen et al. | PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation | |
| ES2918375T3 (es) | Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK | |
| JP7847576B2 (ja) | がんの治療のための組み合わせ | |
| JP2021522211A5 (https=) | ||
| Chen et al. | Inhibition of mTORC2 induces cell-cycle arrest and enhances the cytotoxicity of doxorubicin by suppressing MDR1 expression in HCC cells | |
| JP2019510832A5 (https=) | ||
| JP2019519519A (ja) | 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物 | |
| KR20180126497A (ko) | 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법 | |
| JP2017508789A5 (https=) | ||
| Zanjirband et al. | Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer | |
| JP2018520195A5 (https=) | ||
| ES2732445T3 (es) | Diseño basado en la racionalidad de una terapia específica para el cáncer | |
| JP2018520352A5 (https=) | ||
| JP2017528524A5 (https=) | ||
| JP2015500209A5 (https=) | ||
| JP2014530897A5 (https=) | ||
| JP2016525097A5 (https=) | ||
| WO2016200726A1 (en) | Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors | |
| JP2024028924A (ja) | Ｃｂｍシグナロソーム複合体を標的にすることにより、制御性ｔ細胞に腫瘍微小環境の炎症を引き起こさせる方法 | |
| JP2018527295A5 (https=) | ||
| Mordant et al. | Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination |